Hope is still high that the number of coronavirus cases can soon be cut down, while those who’ve taken precautions by isolating themselves will soon emerge unscathed.
Meantime, a couple of companies are scoring big with waves they are making against the deadly virus.
For starters, Todos Medical Ltd. (OTC:TOMDF), with headquarters in Israel and in New York, is a pre-commercial stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders.
The company has entered into a non-exclusive distribution agreement with 3DMedicine Science & Technology Co (3DMed), a China-based cancer precision medicine company, for distribution in the U.S. and Israel of 3DMed’s ANDiS® SARS-CoV-2 Detection Kit (COVID), ANDiS® SARS-CoV-2 & Influenza A/B Detection Kit (COVID/Flu) and its proprietary ANDiS®350 3DMed Automated Solution countertop real-time PCR machine.
Todos shares sprinted late Tuesday afternoon, acquiring 1.6 cents, or 40%, to 5.6 cents, on volume of 3.2 million shares.
Elsewhere, Montreal-based Elixxer Ltd. (TSX-Venture:ELXR) told investors its Italian pharmaceutical partner, Freia Farmaceutici, has successfully launched its topical hand sanitizer, Dermogel, in Italy with an initial block of 10,000 units. The first batch of 4.000 bottles, from its first 10,000 unit manufacturing run, sold out within five days (likely to no one’s surprise, given that country’s recent virus misfortunes).
Freia’s manufacturing and supply chains are open and the second batch of 34,000 units are on order. Further manufacturing runs are planned as demand increases.
In addition to Italy, Elixxer is assisting Freia to expand Dermogel sales into the U.S. and the U.K. having secured initial orders for the U.K. of 50,000 units.
ELXR shares increased two cents, or 80%, to 4.5 cents, on volume of 4.3 million.